Cefpodoxime proxetil - Generic Drug Details

What are the generic drug sources for cefpodoxime proxetil and what is the scope of patent protection?

Cefpodoxime proxetil is the generic ingredient in three branded drugs marketed by Sankyo, Aurobindo Pharma Ltd, Chartwell Rx, Sun Pharm Inds Ltd, Pfizer, Alkem Labs Ltd, Anda Repository, Aurobindo Pharma, and Sandoz, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for cefpodoxime proxetil. Nine suppliers are listed for this compound.

Summary for cefpodoxime proxetil

US Patents:	0
Tradenames:	3
Applicants:	9
NDAs:	12
Drug Master File Entries:	9
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Drug Prices:	Drug price trends for cefpodoxime proxetil
What excipients (inactive ingredients) are in cefpodoxime proxetil?	cefpodoxime proxetil excipients list
DailyMed Link:	cefpodoxime proxetil at DailyMed

See drug prices for cefpodoxime proxetil

Recent Clinical Trials for cefpodoxime proxetil

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Entasis Therapeutics	Phase 1
James Graham Brown Cancer Center	Early Phase 1
Julio Ramirez	Early Phase 1

See all cefpodoxime proxetil clinical trials

Pharmacology for cefpodoxime proxetil

Drug Class

Cephalosporin Antibacterial

Anatomical Therapeutic Chemical (ATC) Classes for cefpodoxime proxetil

J01DD	Third-generation cephalosporins
J01D	OTHER BETA-LACTAM ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for cefpodoxime proxetil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Ltd	CEFPODOXIME PROXETIL	cefpodoxime proxetil	TABLET;ORAL	065083-001	Aug 20, 2003		DISCN	No	No
Aurobindo Pharma	CEFPODOXIME PROXETIL	cefpodoxime proxetil	TABLET;ORAL	065370-001	Jun 11, 2007	AB	RX	No	No
Sun Pharm Inds Ltd	CEFPODOXIME PROXETIL	cefpodoxime proxetil	FOR SUSPENSION;ORAL	065082-002	May 31, 2002		DISCN	No	No
Sankyo	BANAN	cefpodoxime proxetil	FOR SUSPENSION;ORAL	050688-002	Aug 7, 1992		DISCN	No	No
Alkem Labs Ltd	CEFPODOXIME PROXETIL	cefpodoxime proxetil	TABLET;ORAL	210568-001	May 18, 2022	AB	RX	No	No

Market Dynamics and Financial Trajectory for Cefpodoxime Proxetil

Last updated: February 3, 2026

Summary

Cefpodoxime proxetil is a third-generation oral cephalosporin antibiotic primarily used to treat bacterial infections such as respiratory tract infections, otitis media, urinary tract infections, and skin infections. The drug’s market landscape is influenced by increasing antibiotic resistance, rising prevalence of bacterial infections, and expanding indications in emerging markets. This report analyzes the current market dynamics, key financial metrics, growth drivers, competitive landscape, regulatory environment, and forecasted trajectory for Cefpodoxime proxetil through 2030.

---

1. Market Overview and Scope

Parameter	Details
Therapeutic Class	Cephalosporin Antibiotic
Approved Indications	Respiratory, Urinary Tract, Skin, Soft tissue infections
Formulations	Oral tablets, suspension
Target Geography	North America, Europe, Asia-Pacific, Latin America
Estimated Market Size (2022)	USD 1.2 billion
CAGR (2023-2030)	5–6%, depending on region

---

2. Market Drivers

A. Rising Incidence of Bacterial Infections
The global burden of respiratory and urinary tract infections is increasing due to population growth, urbanization, and environmental factors. WHO estimates suggest over 2 billion cases of bacterial respiratory infections annually.

B. Expanding Indications and Off-label Use
Approval for broader indications and off-label use in pediatric populations extend market potential.

C. Growing Healthcare Infrastructure in Emerging Markets
Improved access to healthcare in Asia-Pacific, Latin America, and Africa enhances demand.

D. Favorable Pharmacokinetics and Safety Profile
Compared to earlier generations, cefpodoxime offers better oral bioavailability, once-daily dosing, and a tolerable safety profile, increasing prescriber preference.

---

3. Market Restraints and Challenges

Challenge	Impact
Antibiotic Resistance	Rising resistance diminishes efficacy, leading to reduced use
Competition from Generics	Patent expiration has led to generic proliferation, impacting margins
Regulatory and Reimbursement Policies	Increasing drug approval barriers and cost containment policies

Antimicrobial stewardship programs are increasingly restricting antibiotic use, affecting sales forecasts.

---

4. Competitive Landscape

Company	Product Name	Market Share (2022)	Key Differentiator
Pfizer (Brands: Zmax, others)	Cefpodoxime Proxetil	30%	Brand recognition, broader indication approvals
Teva	Generic Cefpodoxime	25%	Cost competitiveness, extensive distribution network
Mylan (now part of Viatris)	Generic Cefpodoxime	15%	Price advantage, regional market focus
Others	Various generics	30%	Niche markets, local brands

Patent expirations began circa 2018 in key markets, accelerating generics’ entry.

---

5. Regulatory Environment and Key Policies

Region	Regulatory Body	Regulations Impacting Cefpodoxime Proxetil	Notable Policies
US	FDA	Generic approval via ANDA	Steep approval requirements for generics
EU	EMA	Transparency and post-marketing surveillance	Emphasis on antimicrobial stewardship
China, India, Brazil	NMPA, DCGI, ANVISA	Rapid registration for generics	Price controls and reimbursement strategies

Stringent regulations in developed markets influence market entry strategies.

---

6. Financial Trajectory (2023–2030)

Current Financial Snapshot (2022)

Metric	USD Million	Notes
Market Size	1,200	Estimated global sales
Market Share (Major Players)		Pfizer (30%), Teva (25%), Mylan (15%), Others (30%)
Average Price per Unit	USD 10–20	Variability based on formulation & region

Forecasted Growth (2023–2030)

Year	Projected Market Size (USD Million)	CAGR	Key Factors
2023	1,250	4.2%	Market resilience
2025	1,430	6.0%	Rising bacterial infections, new approvals
2027	1,650	6.1%	Increased generic penetration, emerging markets
2030	1,950	6.2%	Expansion into novel indications, antimicrobial resistance scenarios

Revenue Breakdown (by region, approximate 2022 percentages)

Region	Revenue Share	CAGR (2023–2030)	Key Growth Drivers
North America	45%	4–5%	Market maturity, antimicrobial resistance challenges
Europe	25%	3–4%	Strategic market saturation, prescribing trends
Asia-Pacific	20%	7–8%	Healthcare infrastructure expansion, rising infections
Latin America & Middle East	10%	7–8%	Growth in generic use, increasing healthcare access

---

7. Market Segmentation and Indication-wise Trends

Segment	Share of Market	CAGR (2023–2030)	Notes
Respiratory Tract Infections	40%	5.5%	Primary indication, frequent prescriptions
Urinary Tract Infections	35%	5.8%	Growing prevalence, off-label use
Skin and Soft Tissue Infections	15%	4.8%	Stable, influenced by skin infection rates
Others	10%	3.0–4.0%	Less significant, including otitis media

8. Pricing Trends and Reimbursement

• Premium pricing persists in some regions for branded versions.
• Price erosion is evident due to large-scale genericization.
• Reimbursement policies favor cost-effective generics, aligning profitability with volume sales.

---

9. Impact of Antimicrobial Resistance and Stewardship

Resistance Trends	Effect on Market
Beta-lactamase production in bacteria	Reduced Cefpodoxime efficacy, limiting use
Increased stewardship initiatives	Constraints on prescribing antibiotics, including Cefpodoxime

Addressing resistance-related challenges requires innovation in formulation and combination therapy development.

---

10. Future Outlook and Strategic Opportunities

Opportunity	Description
Development of Fixed-Dose Combinations	Enhances compliance and therapeutic efficacy
Expansion into Novel Indications	Use in intra-abdominal infections, community-acquired pneumonia
Novel Formulations	Extended-release or combination with beta-lactamase inhibitors
Enhanced Market Penetration in Emerging Countries	Focus on local manufacturing, licensing, and distribution

Innovation in resistance mitigation and strategic regional expansion will shape long-term profitability.

---

Key Takeaways

• The global Cefpodoxime proxetil market is projected to grow at a compound annual growth rate of approximately 6% through 2030.
• Expanding indications, generic proliferation, and growing infection prevalence are essential growth drivers.
• The market faces challenges from antimicrobial resistance, regulatory hurdles, and price compression.
• Emerging markets will be critical in driving volume growth, especially in Asia-Pacific.
• Innovation, including combination therapies and formulation improvements, remains vital to penetrate resistant bacterial strains and expand indications.

---

FAQs

Q1: How does antimicrobial resistance impact the Cefpodoxime proxetid market?
Antimicrobial resistance diminishes drug efficacy, leading prescribers to shift towards alternative therapies, thereby constraining market growth and prompting innovation in combination drugs.

Q2: What are the primary regions contributing to Cefpodoxime proxetil sales?
North America accounts for approximately 45%, with Asia-Pacific and Europe contributing 20–25% each. Emerging markets like Latin America and the Middle East are experiencing rapid growth.

Q3: How do patent expirations influence the market trajectory?
Patent expirations starting in 2018 have facilitated a surge of generic Cefpodoxime proxetil products, reducing prices and expanding access but compressing margins for branded companies.

Q4: What are the future growth opportunities for Cefpodoxime proxetil manufacturers?
Expanding indications, developing combination therapies, focusing on resistant bacterial strains, and expanding into underserved geographies present significant opportunities.

Q5: How are regulatory policies shaping Cefpodoxime proxetil market access?
Stringent approval processes in developed markets like the US and EU slow new product entry, whereas emerging markets' regulatory pathways are more flexible, potentially accelerating growth.

---

References

1. World Health Organization. “Bacterial infections and antibiotic resistance,” 2021.
2. IQVIA. “Global antibiotics market report,” 2022.
3. FDA Drug Approvals and Guidelines. U.S. Food and Drug Administration, 2022.
4. EMA Public Assessment Reports. European Medicines Agency, 2022.
5. MarketResearch.com. “Cephalosporin antibiotics market forecast,” 2022.

---

This analysis provides a comprehensive overview to inform strategic decision-making regarding Cefpodoxime proxetil market investments and positioning.